Samaritan says Alzheimer's stem cell drug progressing with promising results

By E. Janene Geiss

Philadelphia, March 22 - Samaritan Pharmaceuticals Inc. said Wednesday that its Alzheimer's adult stem cell drug SP-sc04, which induces dormant brain neuronal stem cells to differentiate rapidly into adult neuron cells, is progressing through preclinical studies with promising results.

"We are extremely pleased with the progress and the potential of SP-04. Although it is early stage, each preclinical study we accomplish gives us hope that we might have an extraordinary treatment for the mind robbing disease of Alzheimer's," Janet Greeson, chief executive officer of Samaritan, said in a company statement.

Samaritan is a Las Vegas biotechnology company that discovers, develops and commercializes innovative therapeutics for AIDS, Alzheimer's, cancer and heart disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.